Obefazimod not checked

Abivax S.A. · ABX464

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
19 in total · 5 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Administered once daily, preferably in the morning, with food”In the company’s words, NCT05535946 on ClinicalTrials.gov
Tested for
Ulcerative Colitis (2 trials), Moderately to Severely Active Crohn Disease
Main trialPhase 3
“This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\]. This…”In the company’s words, NCT05535946 on ClinicalTrials.gov
Other names
ABX464

Other drugs for Ulcerative Colitis

All 79 drugs for Ulcerative Colitis

Coming up3

Changes1

Last 90 days

Trials19

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 28 Apr 2026 ABTECT - Maintenance
Phase 2Recruiting Dec 2026 Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Phase 2Active, not recruiting Mar 2028 Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Phase 1Recruiting Apr 2027 Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation
Phase 3Completed 24 Jun 2025 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Phase 3Completed 24 Jun 2025 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
Phase 2/3Terminated 5 Mar 2021 ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
Phase 2/3Withdrawn 19 Sep 2022 Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
Phase 2Completed 30 Aug 2017 ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
Phase 2Completed 25 Jul 2018 ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Phase 2Completed 1 Apr 2021 Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Phase 2Completed 27 Apr 2021 Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
Phase 2Completed 12 Jul 2022 Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
Phase 2Completed 23 Jan 2023 Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
Phase 2Completed 23 Feb 2023 Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
Phase 1/2Completed 27 Dec 2018 A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
Phase 1Completed Jul 2014 ABX464 First in Man Study
Phase 1Completed 18 May 2021 Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Phase 1Completed 18 Feb 2022 Safety and Pharmacokinetics Study in Healthy Japanese Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Obefazimod

Following is part of Solo: you see every change to Obefazimod the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in